It’s our pleasure to announce the presence of MPN screen *Product Description In the world health organization (WHO) classification of tumors of hematopoietic and lymphoid tissues, Philadelphia-negative
myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). In recent studies it was found that, three-quarters of patients
carry the unique JAK2 (V617F) mutation, which is present in about 95% of subjects with PV and in about 60% of those with ET or PMF. Somatic mutations of JAK2 exon 12 are found in
the remaining 5% of patients with PV , whereas mutations of MPL exon 10 are present in about 5% of those with ET or PMF most patients with ET or PMF with nonmutated JAK2 and MPL carry a somatic mutation of CALR, the gene encoding calreticulin. Kit screens JAK-2 gene exon 12 mutations; between amino
acids 530 and 547, JAK-2 exon 14 gene V617F mutation, MPL gene exon 10; S505N, W515A, W515K, W515RL, W515R mutations, CALR gene exon 9; type 1 , type 2 and other
mutations and CSF3R gene; T615A and T618I mutations